One of the most disappointing and debilitating complications
of diabetes is the development of wounds on the foot or lower leg. Once they
form, they can continue for a considerable length of time, prompting to painful
and dangerous infections. New research reveals the role of a specific protein
in keeping up these wounds and suggests that turning around its belongings
could enable guide to wound healing in patients with diabetes.
Researchers found that a
particular protein, thrombospondin-2 (TSP2), is raised in wounds of patients
with diabetes and in addition in animal models of diabetes. To decide whether
TSP2 contributes to delay wound healing, analysts genetically expelled thrombospondin-2
from a mouse model of diabetes and observed improved enhanced healing. The study
shows that TSP2 could be a target for a specific therapy for diabetic wounds.
Treatment for these wounds is
mostly limited to standard wound care, such as moist bandages, removal of
damaged tissue and footwear that reduces pressure on the wound. Despite these
measures, the wounds often persist. In the most severe cases, it becomes necessary
to amputate the affected foot or lower leg.
Most previous work on wound
healing in diabetes has concentrated on the types of cells that are associated
with wound healing such as skin cells, immune cells and the cells that form
blood vessels. By contrast, research focuses on TSP2, a segment of the
extracellular matrix. The extracellular matrix is a meshwork that serves as the
structural foundation for cells, similar to the scaffolding used in
construction. Thrombospondin-2 is a segment of the extracellular matrix that impacts
how the matrix is framed, and also the development and communication of different
types of cells that develop within the matrix.
They also analysed the factors
that influence how much TSP2 the body produces. That part of the study revealed
that TSP2 production increases when blood sugar levels are higher, explaining
why people with diabetes have higher levels of TSP2 than people without
diabetes.
Currently, lab is developing
engineered biomaterials derived from extracellular matrix that lacks TSP2. Researcher’s
idea is to apply such materials to diabetic wounds in mouse models in order to
evaluate their efficacy. Going forward, additional research will focus around
either inhibiting the function or preventing the production of thrombospondin-2
in diabetic wounds.
Tiffany Hales
Program Manager | Diabetic 2018
Mail id: diabetes@memeetings.net ; diabetes@mehealthevents.org
Its really good website. Thanks for giving full information about Diabetic Footwear.
ReplyDelete